8-K: Clarivate Reports Mixed Q2 2024 Results, Reaffirms Full-Year Outlook

Clarivate's second quarter results show a revenue decrease, but the company reaffirms its 2024 outlook and anticipates a return to organic growth in the second half of the year.

Summary

• Clarivate reported a 2.8% decrease in revenue to $650.3 million for the second quarter of 2024, primarily due to the divestiture of Valipat and unfavorable foreign exchange rates.
• Organic revenue decreased by 0.6%, with subscription revenue increasing by 0.7% offset by declines in re-occurring and transactional revenues.
• The company experienced a net loss of $304.3 million, or $0.46 per diluted share, and adjusted net income decreased by 6.6% to $142.2 million, or $0.20 per diluted share.
• Adjusted EBITDA decreased by 3.7% to $274.4 million, with an adjusted EBITDA margin of 42.2%, a decrease of 40 basis points.
• Net cash from operating activities was $126.2 million, a decrease of $36.2 million, and free cash flow was $60.3 million, a decrease of $44.5 million.
• For the first six months of 2024, revenue decreased by 2.0% to $1,271.5 million, with a net loss of $379.3 million, or $0.61 per diluted share.
• The company reaffirmed its full-year 2024 outlook, expecting revenue between $2.57 billion and $2.67 billion, organic revenue growth between 0% and 2%, adjusted EBITDA between $1.055 billion and $1.115 billion, and free cash flow between $420 million and $500 million.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company reaffirms its outlook and highlights positive developments like new product launches and improved renewal rates, the financial results show significant declines in revenue, profit, and cash flow. The company is facing headwinds and needs to demonstrate a return to growth in the second half of the year.

Positives

• Subscription revenues saw a 0.7% organic increase in Q2, driven by price increases.
• The company launched several new product offerings across all three segments.
• Customer response to operational and product improvements has been positive, leading to improved renewal rates and new customer wins.
• Clarivate is seeing a stabilization in trademark search volumes.
• Derwent renewal rates increased by 250 basis points compared to the same period last year.
• The company acquired Rowan TELS, a patent drafting and prosecution provider, to enhance AI-enabled tools for IP attorneys.
• Clarivate is implementing a 2 Releases a Year (2RaY) model for key R&D products to better meet customer needs.
• The company has a strong cash flow and plans a more balanced approach to capital allocation in the second half of 2024.
• The company won a seven-figure state-wide, multi-year content aggregation deal in the US, displacing a key competitor.

Negatives

• Total revenues decreased by 2.8% in Q2 and 2.0% for the first six months of 2024.
• Net loss was $304.3 million for Q2 and $379.3 million for the first six months of 2024.
• Adjusted net income decreased by 6.6% in Q2 and 13.2% for the first six months of 2024.
• Adjusted EBITDA decreased by 3.7% in Q2 and 5.0% for the first six months of 2024.
• Free cash flow decreased by 42.5% in Q2 and 37.0% for the first six months of 2024.
• Re-occurring revenues decreased by 2.2% in Q2 and 3.5% for the first six months of 2024.
• Transactional and other revenues decreased by 10.3% in Q2 and 10.1% for the first six months of 2024.
• The company experienced a decline in net cash provided by operating activities.
• The Life Sciences & Healthcare segment is facing headwinds due to cost-cutting initiatives by major pharmaceutical companies.

Risks

• The company's performance is subject to fluctuations in foreign exchange rates.
• The divestiture of Valipat negatively impacted revenue.
• The company faces challenges in the Life Sciences & Healthcare segment due to customer budget cuts.
• There is a risk that the company's assumptions and estimates may not prove to be accurate.
• The company's ability to return to organic growth in the second half of the year is not guaranteed.
• The company's free cash flow is expected to be at the low end of the guidance range due to higher capital spending and working capital requirements.
• The company's transactional sales are facing headwinds in content due to softer one-time budgets in the academic fiscal year.

Future Outlook

Clarivate reaffirmed its full-year 2024 outlook, expecting revenue between $2.57 billion and $2.67 billion, organic revenue growth between 0% and 2%, adjusted EBITDA between $1.055 billion and $1.115 billion, and free cash flow between $420 million and $500 million. The company anticipates a return to organic growth in the second half of the year.

Management Comments

• Jonathan Gear, Chief Executive Officer, stated that the company continues to invest in innovation and make progress on its strategy of returning to growth.
• Jonathan Gear noted that customers are responding positively to operational and product improvements, leading to improved renewal rates and new customer wins.
• Jonathan Collins, Executive Vice President and Chief Financial Officer, mentioned that the second quarter results were in line with expectations and that the company plans a more balanced approach to capital allocation in the second half of 2024.

Industry Context

Clarivate's results reflect broader trends in the information services industry, including the impact of economic uncertainty and cost-cutting measures by major clients, particularly in the pharmaceutical sector. The company's focus on AI-enabled solutions and new product launches aligns with the industry's move towards advanced technology and data analytics.

Comparison to Industry Standards

• Clarivate's revenue decline of 2.8% in Q2 is worse than some of its peers in the information services sector, which have shown more resilience in subscription-based models.
• Companies like RELX Group and Thomson Reuters have demonstrated stronger organic growth in their recent reports, indicating that Clarivate is facing specific challenges in its market segments.
• Clarivate's adjusted EBITDA margin of 42.2% is comparable to some industry benchmarks, but the decrease of 40 basis points suggests a need for improved cost management.
• The decrease in free cash flow is a concern, as companies like S&P Global and Moody's have maintained stronger cash generation, which is crucial for investments and shareholder returns.
• The company's focus on AI and new product launches is in line with industry trends, but the impact on revenue growth is yet to be fully realized.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue, profit, and cash flow, but may be reassured by the reaffirmed full-year outlook and the company's plans for a return to growth.
• Employees may be affected by the company's restructuring and cost-cutting measures.
• Customers may benefit from the new product offerings and improved services.
• Suppliers may be impacted by the company's cost-cutting initiatives.
• Creditors may be concerned about the decrease in cash flow.

Next Steps

• The company will host a conference call and webcast to review the results.
• Clarivate plans to take a more balanced approach to capital allocation during the second half of 2024.
• The company will continue to focus on product innovation and customer engagement to drive growth.
• The company will continue to monitor and manage the impact of foreign exchange rates.

Key Dates

Keywords

Clarivate, Financial Results, Earnings, Revenue, EBITDA, Free Cash Flow, Organic Growth, Subscription Revenue, Intellectual Property, Life Sciences, Academia, Government, Adjusted EPS